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Editorial on the Research Topic
Cell Stress, Metabolic Reprogramming, and Cancer
The hallmarks of cancer comprise six biological capabilities acquired during the multistep 
development of human tumors: sustaining proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion 
and metastasis (1). Mitochondria, beyond being the site of aerobic respiration, are at the crossroads 
of a variety of metabolic and signaling pathways resulting key regulatory organelles in cell life 
and death decision. Thus, it is no surprise that genomic, functional, and structural mitochondrial 
alterations have been associated with cancer and that mitochondria have become a pharmacological 
target in cancer therapy (2). Proliferating tumor cells show increased glycolysis and convert the 
majority of glucose to l-lactate, even in normoxic conditions. This is known as the Warburg effect. 
Actually, in many tumors, mitochondria are not defective in oxidative phosphorylation, and in the 
last decade, the molecular basis of Warburg effect has been reconsidered in the context of a set of 
concerted changes in energy metabolism and mitochondrial function that support tumorigenesis. 
This process, referred to as reprogramming of energy metabolism, is an emerging hallmark of cancer 
development (3, 4). This Research Topic presents one review, five mini-reviews, and an opinion 
article on the achievements and perspectives of studies on important aspects of cancer cell metabolic 
reprogramming whose mechanisms and regulation are still largely elusive. It also sheds light on 
certain novel functional components, which rewires cell metabolism in tumor transformation.
Metabolic reprogramming is driven by oncogenic changes of specific cell-signaling pathways 
and tumor microenvironment (5). The Mini-Reviews by Iommarini et  al. (6) and Dahl and 
Aird (7) highlight what is currently known about the non-canonical function and regulation of 
hypoxia-inducible factor 1 alpha (HIF-1α) and ataxia-telangiectasia mutated (ATM) protein 
kinase, respectively. Iommarini et al. (6) review and discuss the non-canonical regulation of HIF-
1α expression and stabilization in cancer cells, focusing on factors, which cause pseudohypoxia 
(HIF-1α stabilization in normoxic conditions) or fail to stabilize HIF-1α in low oxygen atmosphere 
(pseudonormoxia). The ATM protein kinase has been extensively studied for its role in the DNA 
damage response and its association with the disease ataxia telangiectasia. Dahl and Aird’s review (7) 
highlights our current knowledge about ATM’s regulation of carbon metabolism, the implication of 
these pathways in cancer, and the development of ATM inhibitors as therapeutic strategies for cancer.
It is well established that glucose is uniquely capable of supporting Warburg metabolism (or 
aerobic glycolysis), in which pyruvate is converted to lactate through a process that is coupled to ATP 
production in the cytoplasm. Such metabolic reprogramming and nutrient sensing is an elaborate 
way by which cancer cells respond to high bioenergetic and anabolic demands during tumorigenesis. 
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Ždralević et al. (8) in their Mini-Review discuss the benefits and 
limitations of disrupting fermentative glycolysis at different 
levels of the pathway in order to find the most effective mode 
to overcome cancer cell metabolic plasticity that seriously limits 
the use of glycolysis inhibition for impeding tumor growth. With 
this respect, in view of the existence of a mitochondrial l-lactate 
dehydrogenase (m-l-LDH), Passarella and Shurr (9) propose 
in their Opinion a revision of the Cori cycle in all types of cells 
where mitochondrial metabolism of l-lactate is active.
Beyond the shift of glucose metabolism to aerobic glycolysis, 
some cancer cells are considered “glutamine addicted” because 
their growth and proliferation rates depend on the availability 
of this amino acid. This, together with the role of amino acid 
metabolism in tumorigenesis, is one of the key aspects of cancer 
cell metabolism, which is still matter of intense investigations. The 
Review by Vučetić et al. (10) provides the first unified review on 
the amino acid dependency of cancer antioxidant defense, a topic 
that has received more attention recently. Furthermore, the Mini-
Review by Scalise et al. (11) provides a deep insight into glutamine 
transport and mitochondrial metabolism in cancer cell growth, 
highlighting glutamine transporters of plasma membrane, the 
key enzyme glutaminase, and other proteins involved glutamine 
metabolism as novel targets for anti-cancer drug development.
Beyond the metabolic shift toward glycolysis, typical of 
cancer cells, several evidences have shown that mitochondrial 
dysfunction provides survival advantage to cancer cells, 
suggesting that mitochondria have a tumor suppressor function 
(5). Mitochondrial dysfunction has been implicated in cancer 
chemoresistance (12). The association between mitochondrial 
dysfunction and progression to a metastatic phenotype is gradually 
emerging. Epithelial-to-mesenchymal transition (EMT) allows 
epithelial cancer cells to assume mesenchymal features, endowing 
them with enhanced motility and invasiveness, thus enabling 
cancer dissemination and metastatic spread. The Mini-Review by 
Guerra et al. (13) in this Research Topic gives an overview on the 
mechanistic link between EMT and mitochondrial dysfunction 
fostering the identification of the molecular determinants of 
the mitochondria-nucleus communication network linking 
mitochondrial dysfunction with EMT activation, which may 
provide useful therapeutic targets for treatment and prevention 
of metastatic cancer.
The contributions to this Research Topic deal with investigations 
at the leading edge of cancer research and provide an overview 
on key cellular processes and components, which are the basis 
of metabolic reprogramming of cancer cells. Inflammation has 
also been recognized as a hallmark of cancer and is known to 
play an essential role in the development and progression of most 
cancers, even those without obvious signs of inflammation and 
infection (14). Warburg metabolism is a hallmark of immune cells 
that have the potential to cause inflammation. Recently, Kornberg 
et al. gave proof of concept that aerobic glycolysis is a therapeutic 
target for regulating inflammation (15), further confirming the 
possibility that targeting key enzymes within metabolic pathways 
will provide new therapeutic options for cancer.
This Research Topic brings witness that research on metabolic 
reprogramming of cancer cells is coming of age and will still bring 
with it exciting results to lay the bases for the development of 
new therapies and the implementation of nutritional regimen for 
a healthy life as well as the improvement of anti-cancer therapies.
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